Rohit P Ojha1, Tabatha N Offutt-Powell2, James G Gurney3. 1. Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee. Electronic address: rohit.ojha@stjude.org. 2. Office of Infectious Disease Epidemiology, Division of Public Health, Delaware Health and Social Services, Dover, Delaware. 3. Department of Epidemiology, Biostatistics, and Environmental Health, University of Memphis School of Public Health, Memphis, Tennessee.
Abstract
BACKGROUND: A large proportion of long-term survivors of childhood cancer have treatment-related adverse cardiac and pulmonary late-effects, with related mortality. Consequently, this population of approximately 379,000 individuals in the U.S. is at high risk of complications from influenza infections. PURPOSE: To estimate influenza vaccination coverage overall and among subgroups of adult survivors of pediatric cancer aged 18-64 years and to compare coverage with the general adult U.S. population. METHODS: Data from the 2009 Behavioral Risk Factor Surveillance System were analyzed in 2013 using binomial regression to estimate influenza vaccination coverage differences (CDs) and corresponding 95% confidence limits (CLs) between adult survivors of pediatric cancer and the general U.S. population. Analyses were stratified by demographic characteristics and adjusted for design effects, non-coverage, and non-response. RESULTS: Influenza vaccination coverage was 37% for adult pediatric cancer survivors overall and 31% for the general adult U.S. population (CD=6.3%, 95% CL=0.04%, 13%). Dramatically lower coverage was observed for non-Hispanic black survivors (6%) than for non-Hispanic blacks in the general U.S. population (26%; CD=-18%, 95% CL=-25%, -11%). CONCLUSIONS: Although influenza vaccination coverage was modestly higher among adult survivors of pediatric cancer than the general U.S. population, coverage was less than desirable for a population with a high prevalence of cardiopulmonary conditions and early mortality, and far lower than the Healthy People 2010 goal of 60% or Healthy People 2020 goal of 80% for the general population.
BACKGROUND: A large proportion of long-term survivors of childhood cancer have treatment-related adverse cardiac and pulmonary late-effects, with related mortality. Consequently, this population of approximately 379,000 individuals in the U.S. is at high risk of complications from influenza infections. PURPOSE: To estimate influenza vaccination coverage overall and among subgroups of adult survivors of pediatric cancer aged 18-64 years and to compare coverage with the general adult U.S. population. METHODS: Data from the 2009 Behavioral Risk Factor Surveillance System were analyzed in 2013 using binomial regression to estimate influenza vaccination coverage differences (CDs) and corresponding 95% confidence limits (CLs) between adult survivors of pediatric cancer and the general U.S. population. Analyses were stratified by demographic characteristics and adjusted for design effects, non-coverage, and non-response. RESULTS: Influenza vaccination coverage was 37% for adult pediatric cancer survivors overall and 31% for the general adult U.S. population (CD=6.3%, 95% CL=0.04%, 13%). Dramatically lower coverage was observed for non-Hispanic black survivors (6%) than for non-Hispanic blacks in the general U.S. population (26%; CD=-18%, 95% CL=-25%, -11%). CONCLUSIONS: Although influenza vaccination coverage was modestly higher among adult survivors of pediatric cancer than the general U.S. population, coverage was less than desirable for a population with a high prevalence of cardiopulmonary conditions and early mortality, and far lower than the Healthy People 2010 goal of 60% or Healthy People 2020 goal of 80% for the general population.
Authors: In Young Cho; Jung Eun Yoo; Hyeonyoung Ko; Dong Wook Shin; Ji Won Lee; Hee Jo Baek; Nack-Gyun Chung; Ki Woong Sung; Yun-Mi Song Journal: J Cancer Surviv Date: 2019-11-04 Impact factor: 4.442
Authors: Echo L Warner; Perla L Vaca Lopez; Deanna Kepka; Karely Mann; Heydon K Kaddas; Douglas Fair; Mark Fluchel; Elizabeth D Knackstedt; Samantha T Pannier; Laura Martel; Anne C Kirchhoff Journal: J Cancer Surviv Date: 2020-05-26 Impact factor: 4.442
Authors: Hilary C Tanenbaum; Lanfang Xu; Erin E Hahn; Julie Wolfson; Smita Bhatia; Kim Cannavale; Robert Cooper; Chun Chao Journal: Prev Med Rep Date: 2020-12-01